Quanterix

Quanterix helps scientists and doctors detect diseases earlier using sensitive lab instruments. Its products measure tiny amounts of disease markers in blood or tissue. Hospitals and research labs use these tools to study conditions like Alzheimer’s and cancer.

Lab Gadgets and Science Kits: What’s on Offer?

• Digital Immunoassay Platforms (Simoa): Automated instruments for detecting proteins at very low levels; accounted for 76% of 2025 product revenue; used by research labs and hospitals.
• Spatial Biology Platforms: Systems for analyzing many proteins in tissue samples; accounted for $21.9 million of 2025 product revenue and $11.8 million of 2025 service and other revenue; used in cancer and neurology research.
• Consumables: Assay kits, reagents, and single-use parts; recurring sales tied to installed instruments.
• Contract Research & Clinical Lab Services: Custom sample testing and assay development for pharmaceutical and academic clients.
• Diagnostics (LucentAD): Blood tests for Alzheimer’s disease; growing share after 2024 launch; used by clinics and reference labs.

Growth Spurts and Bold Moves

• Acquired Akoya Biosciences (spatial biology) in July 2025, adding $33.7 million revenue that year.
• Bought Emission, Inc. (magnetic bead tech) in January 2025 to expand technology base.
• Launched LucentAD Complete Alzheimer’s blood test in November 2024; received U.S. Medicare reimbursement approval in November 2025.
• Entered 13 new hospital and lab partnerships in 2025, reaching 25 partners by year-end.
• Expanded internationally, with 40% of 2025 revenue from outside North America.

Why Quanterix Catches the Eye

Quanterix operates in over 40 countries, selling directly in North America and Europe and through distributors elsewhere. Its proprietary technology allows detection of disease markers at much lower levels than standard lab tests. The company’s recurring revenue model is supported by a large installed base of over 2,500 instruments worldwide.

Five Things You Need to Know

• 2025 revenue was $138.9 million, up 1% from 2024.
• Product revenue rose 17% in 2025, while service revenue fell 14%.
• Gross margin dropped to 47% in 2025, down from 60% in 2024.
• Operating loss widened to $125.5 million in 2025, up from $52.6 million in 2024.
• International sales made up 40% of total revenue in 2025.

Bottom Line

Quanterix has diversified its business through acquisitions and new product launches. The company faces operational challenges but remains focused on innovation in disease detection and research tools.